Skip to main content
Clinical Trials/NCT06381232
NCT06381232
Recruiting
Not Applicable

Collection and Analyses of Physiological, Physical, and Molecular Data From a Diverse Population

Viome1 site in 1 country20,000 target enrollmentJuly 23, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
General Health
Sponsor
Viome
Enrollment
20000
Locations
1
Primary Endpoint
Molecular Determinants of Health and Disease
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The purpose of the study is to collect and analyze physiological, physical, and molecular data from a diverse population to increase our understanding of how such parameters are associated with health and disease.

Detailed Description

The analyses conducted by Viome will include, but are not limited to: genetic, transcriptomic, metabolomic, physiological, and physical. The samples collected from participants may include any of these: stool, blood, saliva, cheek swab, vaginal, breast milk/colostrum, nasal swabs or washes, and urine. Study participants will collect the clinical samples and ship them to Viome labs or CROs (Contract Research Organizations), where they will be analyzed. The objective of the study is to establish which foods correspond with increased wellness, and which foods correspond to decreased wellness. The study hypothesis is that by monitoring the patterns of food intake and lifestyle parameters, in conjunction with non-invasive sample testing, personalized diet and lifestyle recommendations can be elucidated.

Registry
clinicaltrials.gov
Start Date
July 23, 2018
End Date
July 23, 2028
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Viome
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Anyone that resides in the US at the time of enrollment.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Molecular Determinants of Health and Disease

Time Frame: 10 years

We measure thousands of transcript levels in multiple clinical samples. The primary outcome measures are changes in quantitative gene expression, microbial or human, as a result of transitioning from a healthy state to a disease.

Study Sites (1)

Loading locations...

Similar Trials